phrykt

Monopar Therapeutics (MNPR): who owns it and who trades it

As of Nov 16, 2026, MNPR insiders reported 28 open-market sales worth $4.9M and 1 purchase worth $105K in the last 12 months, with 93% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chandler Robinson (CEO), with $2.6M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Monopar Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MNPR

96 funds and institutions reported MNPR shares worth $577M at the end of Q2 2026, about 93% of the company. The largest holder is Jupiter Topco LLC with 19.6%.

Funds and institutions (13F) 93%Everyone else 7%

10 largest owners, by share of the company

Jupiter Topco LLC19.6%
Ra Capital Management, L.P.10.0%
BlackRock, Inc.5.2%
Deerfield Management Company, L.P.4.8%
Saturn V Capital Management LP4.7%
Siren, L.L.C.4.0%
ADAR1 Capital Management, LLC3.3%
Polar Capital Holdings Plc3.2%
Vanguard Capital Management LLC3.1%
Adage Capital Partners Gp, L.l.c.3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC1.31M19.61%$122MNew
Ra Capital Management, L.P.667,2079.97%$61.8MNo change
BlackRock, Inc.348,8195.21%$32.3M+10%
Deerfield Management Company, L.P.323,7454.84%$30MNo change
Saturn V Capital Management LP311,9764.66%$28.9M-10%
Siren, L.L.C.270,1184.04%$25MNo change
ADAR1 Capital Management, LLC217,5953.25%$20.1M-18%
Polar Capital Holdings Plc214,4693.20%$19.9M-5%
Vanguard Capital Management LLC209,7113.13%$19.4M-4%
Adage Capital Partners Gp, L.l.c.209,1953.13%$19.4M-32%
TCG Crossover Management, LLC203,3273.04%$18.8M+54%
Wellington Management Group LLP158,4372.37%$14.7M-9%
Orbimed Advisors LLC157,4232.35%$14.6MNew
Candriam S.C.A.143,3392.14%$13.3MNew
Balyasny Asset Management L.P.134,5432.01%$12.5M-1%
Geode Capital Management, LLC112,5781.68%$10.4M+13%
Alyeska Investment Group, L.P.100,0001.49%$9.3MNo change
State Street Corp92,5511.38%$8.6M+5%
Vivo Capital, LLC90,5001.35%$8.4MNo change
Driehaus Capital Management LLC84,0401.26%$7.8M+153%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MNPR insiders reported $105K of open-market purchases and $4.9M of sales. 93% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$105K
1 trades, 1 people
Sales, 12 months
$4.9M
28 trades, 6 people
Sales under a 10b5-1 plan
93%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 4, 2026

Purchases and sales by month

$2.6M$2.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Kim R TsuchimotoDirectorSale plan1,295$70.75$91.6KForm 4
Nov 4, 2026Kim R TsuchimotoDirectorSale plan996$71.35$71.1KForm 4
Nov 4, 2026Kim R TsuchimotoDirectorSale plan600$72.21$43.3KForm 4
Nov 2, 2026Raymond AndersonDirectorSale plan840$66.16$55.6KForm 4
Nov 2, 2026Raymond AndersonDirectorSale plan600$67.06$40.2KForm 4
Nov 2, 2026Raymond AndersonDirectorSale plan200$68.68$13.7KForm 4
Nov 2, 2026Raymond AndersonDirectorSale plan1,502$70.04$105KForm 4
Nov 2, 2026Kim R TsuchimotoDirectorSale plan1,199$70.10$84KForm 4
Oct 1, 2026Christopher M StarrDirectorSale plan4,631$78.09$362KForm 4
Oct 1, 2026Christopher M StarrDirectorSale plan2,970$78.82$234KForm 4
Oct 1, 2026Christopher M StarrDirectorSale plan799$79.67$63.7KForm 4
Sep 24, 2026Chandler RobinsonCEOSale plan600$89.79$53.9KForm 4
Sep 24, 2026Chandler RobinsonCEOSale plan8,368$88.97$745KForm 4
Sep 24, 2026Chandler RobinsonCEOSale plan9,638$87.96$848KForm 4
Sep 24, 2026Chandler RobinsonCEOSale plan10,450$87.15$911KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan700$110.65$77.5KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan602$112.93$68KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan590$113.84$67.2KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan615$109.56$67.4KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan485$108.83$52.8KForm 4
Aug 26, 2026Kim R TsuchimotoDirectorSale plan1,098$111.84$123KForm 4
Aug 26, 2026Patrice RiouxOtherSale plan1$111.26$111Form 4
Aug 25, 2026Raymond AndersonDirectorSale plan646$111.07$71.8KForm 4
Aug 25, 2026Raymond AndersonDirectorSale plan694$110.04$76.4KForm 4
Aug 25, 2026Raymond AndersonDirectorSale plan1,802$113.05$204KForm 4
Aug 25, 2026Raymond AndersonDirectorSale plan646$110.07$71.1KForm 4
Dec 26, 2025Quan Anh VuCFOPurchase1,500$69.95$105KForm 4
Dec 18, 2025Arthur J KlausnerDirectorSale4,660$67.06$312KForm 4
Dec 18, 2025Arthur J KlausnerDirectorSale461$68.09$31.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Chandler RobinsonChief Executive Officer, Director–$2.6MSep 24, 2026
Kim R TsuchimotoDirector–$746KNov 4, 2026
Christopher M StarrDirector–$659KOct 1, 2026
Raymond AndersonDirector–$638KNov 2, 2026
Arthur J KlausnerDirector–$344KDec 18, 2025
Quan Anh VuChief Financial Officer$105K–Dec 26, 2025
Patrice RiouxOther–$111Aug 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MNPR short interest

High short interest. 16.4% of MNPR shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 30%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.10M MNPR shares were sold short, 16.4% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 125,435 shares, buying them all back would take about 8.8 trading days (days to cover).

Shares short, % of all shares

16.4%May 15Oct 3025.3%

Days to cover

8.8May 15Oct 3013.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.10M16.44%-2%125,4358.8
Oct 15, 20261.13M16.81%+4%158,0967.1
Sep 30, 20261.09M16.18%+29%180,4486.0
Sep 15, 2026844,22612.58%-1%117,2297.2
Aug 31, 2026852,42512.70%-4%187,8904.5
Aug 14, 2026887,18813.22%-17%255,2733.5
Jul 31, 20261.07M15.87%-22%312,9283.4
Jul 15, 20261.36M20.33%-10%228,9405.9
Jun 30, 20261.52M22.71%-2%176,4538.6
Jun 15, 20261.56M23.28%-1%124,25012.5
May 29, 20261.58M23.60%+1%185,1048.5
May 15, 20261.57M23.45%-6%195,0398.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Monopar Therapeutics company events

Monopar Therapeutics filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 12, 2026.

  1. Aug 12, 2026ResultsReleased financial results. Filing
  2. Jul 22, 2026AnnouncementShared information with investors. Filing
  3. Jun 30, 2026AnnouncementShared information with investors. Filing
  4. Jun 26, 2026AnnouncementShared information with investors. Filing
  5. Jun 23, 2026VoteReported shareholder vote results. Filing
  6. May 29, 2026AnnouncementShared information with investors. Filing
  7. May 19, 2026AnnouncementShared information with investors. Filing
  8. May 14, 2026ResultsReleased financial results. Filing
  9. Apr 20, 2026AnnouncementShared information with investors. Filing
  10. Mar 27, 2026ResultsReleased financial results. Filing
  11. Mar 2, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Monopar Therapeutics financials

Famous investors that hold MNPR

2 of the 50 well-known investors we track reported holding MNPR in their latest 13F filing. The largest position is Israel Englander's, worth $3.9M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202648,607$3.9M0.0%-3%
Ken Griffin · Citadel AdvisorsQ3 202647,896$3.8M0.0%+29%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MNPR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A16.7%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A16.7%
Oct 27, 2026BlackRock, Inc.13G5.0%
Oct 27, 2026BlackRock, Inc.13G5.0%

Questions about Monopar Therapeutics (MNPR) stock

Who owns the most MNPR stock?

The largest reported owner of Monopar Therapeutics (MNPR) is Jupiter Topco LLC, with 19.6% of the company. In total, 96 funds and institutions reported holding MNPR at the end of Q2 2026, together about 93% of the shares. See the largest owners.

Are MNPR insiders buying or selling?

In the last 12 months, MNPR insiders reported 1 open-market purchase worth $105K and 28 sales worth $4.9M. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in MNPR?

As of Oct 30, 2026, 1.10M MNPR shares were sold short, 16.4% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 125,435 shares, buying them all back would take about 8.8 trading days (days to cover). See the history.

Which famous investors hold MNPR?

2 of the 50 well-known investors we track reported MNPR in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $3.9M. See all holders.

Executive pay

Monopar Therapeutics's chief executive was paid a total of $10.6M for the year ended Dec 31, 2025, up 829% from $1.1M the year before. In the last 12 months, Monopar Therapeutics's executives and directors bought $105K of stock on the open market and sold $4.9M.

Chief executive, total pay$10.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$17.4MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.